{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:40:14Z","timestamp":1767915614720,"version":"3.49.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1016","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:p>Objectives: The aim of the study was to compare differences in dosimetric, clinical and quality-of-life end points among patients treated with helical tomotherapy (HT) and segmental multileaf collimator (SMLC)-based intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma.<\/jats:p>\n               <jats:p>Methods: From June 2005 to August 2009, 30 consecutive patients were treated with IMRT for nasopharyngeal carcinoma to a dose of 70 Gy. 14 patients (47%) were treated using HT and 16 (53%) were treated using SMLC-based IMRT. 28 patients (93%) received concurrent chemotherapy. The patients were evenly balanced between the two radiotherapy groups with respect to clinical and pathological characteristics. Median follow-up was 30 months (range, 6\u201362 months).<\/jats:p>\n               <jats:p>Results: The 2-year estimates of overall survival, local\u2013regional control and progression-free survival were 81%, 87% and 82%, respectively. There were no significant differences in any of these end points with respect to IMRT technique (p&amp;gt;0.05 for all). Dosimetric analysis revealed that patients treated by HT had significantly improved salivary sparing with respect to mean dose (27.3 vs 34.1 Gy, p=0.03) and volume receiving greater than or equal to 30 Gy (31.7% vs 47.3%, p=0.01) to the contralateral (spared) parotid gland. The incidence of Grade 3+ late xerostomia was 13 and 7% among patients treated with SMLC-based IMRT and HT, respectively (p=0.62). The corresponding proportion of patients who subjectively reported \u201ctoo little\u201d or \u201cno\u201d saliva at final follow-up was 38% and 7%, respectively (p=0.04).<\/jats:p>\n               <jats:p>Conclusion: The superior dosimetric outcome observed with HT appeared to translate into moderately improved clinical outcomes with respect to salivary sparing. Prospective trials are needed to validate this gain in the therapeutic ratio.<\/jats:p>","DOI":"10.1259\/bjr\/23807619","type":"journal-article","created":{"date-parts":[[2012,2,6]],"date-time":"2012-02-06T18:58:06Z","timestamp":1328554686000},"page":"e537-e543","source":"Crossref","is-referenced-by-count":23,"title":["Intensity-modulated radiotherapy for nasopharyngeal carcinoma: improvement of the therapeutic ratio with helical tomotherapy <i>vs<\/i> segmental multileaf collimator-based techniques"],"prefix":"10.1093","volume":"85","author":[{"given":"A M","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C C","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Marsano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Purdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"key":"2024050213344717400_b1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0360-3016(91)90030-8","article-title":"Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx.","volume":"20","author":"Leibel","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2001.19.4.1105","article-title":"Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma.","volume":"19","author":"Wolden","year":"2001","journal-title":"J Clin Oncol"},{"key":"2024050213344717400_b3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0360-3016(92)90741-Y","article-title":"Carcinoma of the nasopharynx: factors affecting prognosis.","volume":"23","author":"Perez","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ijrobp.2006.11.052","article-title":"A prospective evaluation of helical tomotherapy.","volume":"68","author":"Bauman","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.radonc.2006.02.009","article-title":"Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy.","volume":"78","author":"Fiorino","year":"2006","journal-title":"Radiother Oncol"},{"key":"2024050213344717400_b6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ijrobp.2006.02.038","article-title":"Intensity-modulated radiation therapy (IMRT) dosimetry of the head and neck: a comparison of treatment plans using linear accelerator-based IMRT and helical tomotherapy.","volume":"65","author":"Sheng","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b7","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC cancer staging manual","author":"Greene","year":"2002"},{"key":"2024050213344717400_b8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2024050213344717400_b10","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1200\/JCO.2008.19.9109","article-title":"Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225.","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"2024050213344717400_b11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0167-8140(01)00449-2","article-title":"Intensity-modulated radiation therapy reduces late salivary toxicity without compromizing tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques.","volume":"61","author":"Chao","year":"2001","journal-title":"Radiother Oncol"},{"key":"2024050213344717400_b12","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2007.07.2351","article-title":"Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficiency.","volume":"70","author":"Jabbari","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ijrobp.2006.06.045","article-title":"Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy.","volume":"66","author":"Braam","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b14","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1200\/JCO.2007.11.5501","article-title":"Prospective randomized study of inensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.","volume":"25","author":"Kam","year":"2007","journal-title":"J Clin Oncol"},{"key":"2024050213344717400_b15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.coc.0000258081.70643.3d","article-title":"Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy.","volume":"30","author":"Scrimger","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"2024050213344717400_b16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0360-3016(99)00247-3","article-title":"Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.","volume":"45","author":"Eisbruch","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/(SICI)1097-0347(199909)21:6<547::AID-HED8>3.0.CO;2-Y","article-title":"Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study.","volume":"21","author":"Ho","year":"1999","journal-title":"Head Neck"},{"key":"2024050213344717400_b18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.21683","article-title":"Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma.","volume":"106","author":"Chen","year":"2006","journal-title":"Cancer"},{"key":"2024050213344717400_b19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ijrobp.2004.08.019","article-title":"Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients.","volume":"61","author":"Pan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-8140(02)00173-1","article-title":"Sensorineural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation.","volume":"65","author":"Honor\u00e9","year":"2002","journal-title":"Radiother Oncol"},{"key":"2024050213344717400_b21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0360-3016(96)00302-1","article-title":"Long-term sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment.","volume":"36","author":"Ho","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2004.11.002","article-title":"Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone.","volume":"62","author":"Yeh","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0360-3016(01)01631-5","article-title":"Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques.","volume":"51","author":"Jen","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0360-3016(97)00580-4","article-title":"Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma.","volume":"40","author":"Lee","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0360-3016(02)02711-6","article-title":"Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time.","volume":"53","author":"Lee","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213344717400_b26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.ijrobp.2007.07.2345","article-title":"Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get?","volume":"69","author":"O'Daniel","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/85\/1016\/e537\/57386775\/bjr_23807619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/85\/1016\/e537\/57386775\/bjr_23807619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T13:37:47Z","timestamp":1714657067000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/85\/1016\/e537\/7450639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":26,"journal-issue":{"issue":"1016","published-online":{"date-parts":[[2014,3,5]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr\/23807619","relation":{},"ISSN":["0007-1285"],"issn-type":[{"value":"0007-1285","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,8,1]]},"published":{"date-parts":[[2012,8,1]]}}}